Decisions about add-on reimbursement for medical devices in France in May

27

Jul 2018

The French National Authority for Health (HAS) released new decisions about add-on and medical aid reimbursement of 21 medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in May.

Four decisions were released for cardiovascular devices:

  • AZURE XT SR MRI SURESCAN, implantable cardiac pacemaker (application for registration, approved)
  • AZURE XT DR MRI SURESCAN, implantable cardiac pacemaker (application for -registration, approved)
  • PERCEPTA CRT-P MRI SURESCAN, implantable cardiac pacemaker (application for registration, approved)
  • PERCEPTA QUAD CRT-P MRI SURESCAN, implantable cardiac pacemaker (application for registration, approved)

Nine decisions were released for prosthesis:

  • TRES, energy return foot (application for registration, approved)
  • GLASSBONE, synthetic bone substitute (application for registration, approved)
  • AVANTAGE 3P PLASMA TIHA and AVANTAGE REVISION (with no cement), acetabular cup with double mobility (application for registration, approved)
  • A2T, ankle orthosis, (application for registration, approved under generic name)
  • XLMOB (without cement), acetabular cup with double mobility (application for registration, rejected due to insufficient expected benefit)
  • XLMOB (with cement), acetabular cup with double mobility (application for registration, rejected due to insufficient expected benefit)
  • GALILEA (with cement), acetabular cup with double mobility (application for registration, rejected due to insufficient expected benefit)
  • NANOSTIM, injectable synthetic bone substitute (renewal of registration, approved)

Eight decisions were released for other devices:

  • BARRX, radiofrequency ablation system for Barrett's Esophagus (application for registration, approved on title V)
  • SEQUENT, meniscal repair system (renewal of registration, approved)
  • ACTISORB, active carbon bandage (renewal of registration, approved)
  • PROFORE, multilayer compression system (renewal of registration, approved)
  • PERENNIADURA 303 et PERENNIAFLEX 304, vagus nerve stimulation electrodes (renewal of registration, approved)
  • DEMIPULSE 103 ET DEMIPULSE 104, vagus nerve stimulation generator (renewal of registration, approved)

See list of decisions in French here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

10

Mar 2022

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more

07

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

Read more